European Atherosclerosis Society (EAS) & Congress

European Atherosclerosis Society (EAS) & Congress For more than 50 years the Society’s expertise has been used to teach clinicians how to manage lipid disorders and how to prevent atherosclerosis.

The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”. By offering to our members access to educational materials, and opportunities to take part in Congress and courses, and by providing a forum in which new developments can be discussed, EAS co

ntributes to the development of knowledge in the field, and ultimately to the improved treatment of persons with cardiovascular disease and lipid disorders. In recent years the Society has made a particular effort to recruit young scientists and clinicians also from other related disciplines. What we do
The European Atherosclerosis Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis. EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. Through a regular series of Featured Commentaries EAS puts into perspective topical issues of relevance to our members. The Society organizes an annual Congress for approximately 2000 delegates, and runs a programme of Advanced Courses for both basic scientists and clinicians. EAS Academy is the Society's online e-Learning resource, containing a range of educational material and self-teaching programmes.

In this episode of AtheroTalk, we are privileged to welcome Prof. Heribert Schunkert, recipient of the 2026 EAS Anitschk...
10/09/2026

In this episode of AtheroTalk, we are privileged to welcome Prof. Heribert Schunkert, recipient of the 2026 EAS Anitschkow Prize.

By listening to Prof. Schunkert’s inspiring academic journey and thought-provoking insights regarding the future of cardiovascular disease management, this discussion makes us wonder about how we can include polygenic risk scores in daily clinical practice, how we can improve the care of our patients with familial hypercholesterolemia and about how we can overcome the biggest challenges in cardiometabolic medicine.
🎧 Spotify: https://eas.to/ATHTalkE38S
🎧 Apple Podcasts: https://eas.to/ATHTalkE38A
🎧 Youtube: https://eas.to/ATHTalkE38Y

And now it’s your turn: who deserves to be the next Anitschkow Prize recipient? The 2027 nomination process is open. If there is a researcher whose outstanding contributions to atherosclerosis and related metabolic disorders deserve recognition, consider nominating them: https://eas.to/Anitschkow2027Nom

The Rare Lipid Disorders Course is coming to Italy! 🇮🇹Join us in Rome to learn more about rare genetic disorders of lipi...
07/09/2026

The Rare Lipid Disorders Course is coming to Italy! 🇮🇹

Join us in Rome to learn more about rare genetic disorders of lipid metabolism, including β-sitosterolemia, cerebrotendinous xanthomatosis, lysosomal acid lipase deficiency, disorders of high-density lipoprotein (HDL), and familial hypocholesterolemias.

Register and learn more: https://eas.to/RLDRome

The second event of our CME-accredited series explores the evolving role of imaging and emerging clinical evidence in ca...
04/09/2026

The second event of our CME-accredited series explores the evolving role of imaging and emerging clinical evidence in cardiovascular primary prevention.

Participants will learn how imaging techniques complement SCORE2 and SCORE2-OP risk assessment by improving risk stratification and evaluating atherosclerotic plaque, particularly in individuals at very high cardiovascular risk. The programme will also highlight key findings from recent LDL-C–lowering trials, including VESALIUS, V1P, CORAL-Reef, and ACCLAIM, and discuss their implications for future clinical practice.

Register now: https://eas.to/WebGuide2

The global burden of obesity-related metabolic disease is rising rapidly, driving interconnected cardiovascular, liver, ...
03/09/2026

The global burden of obesity-related metabolic disease is rising rapidly, driving interconnected cardiovascular, liver, kidney, and metabolic complications.

In this Featured Open Lecture, Prof. Kausik K. Ray and Stefano Romeo explore the European Atherosclerosis Society’s new framework for understanding systemic metabolic disease - a multi-organ continuum linking dysfunctional adiposity, insulin resistance, dyslipidaemia, liver and kidney disease, heart failure, and atherosclerotic cardiovascular disease.

Together, they discuss the clinical importance, underlying mechanisms, and how a more integrated approach could transform prevention, treatment, and future research: https://eas.to/OpenSep26

One of the most exciting moments in our calendar has arrived - nominations for the Anitschkow Prize 2027 are officially ...
01/09/2026

One of the most exciting moments in our calendar has arrived - nominations for the Anitschkow Prize 2027 are officially open! 🎉 Do you know a researcher whose outstanding work deserves to be recognised? We’re sure someone has already come to mind!

✨ Start September by giving them the recognition. Nominate your candidate today and help us shine a light on the achievements of an outstanding member of our community. Submit your nomination here: https://eas.to/Anitschkow2027Nom

What have we learned from the Palisade Study, where will it lead future research?Join our webinar that will examine how ...
31/08/2026

What have we learned from the Palisade Study, where will it lead future research?

Join our webinar that will examine how the PALISADE study was designed, conducted and interpreted, alongside a review of plozasiran’s mechanism of action and the role of ApoC-III reduction in triglyceride metabolism. Looking ahead, the session will also explore the future potential of siRNA therapies in hypertriglyceridaemia and related lipid disorders, and consider how plozasiran may be incorporated into clinical practice through real-world patient case discussions.

Register here: https://eas.to/WebPalisadeStudy

28/08/2026

So many paths to explore at European Society of Cardiology Congress - make sure one of them leads to us. As you navigate the latest ideas, conversations & discoveries, take a moment to stop by the EAS booth.

📍 Find us at booth F810 in hall 2B!

28/08/2026

A few final touches. Last-minute adjustments. Every detail falling perfectly into place.

And then? Conversations, connections, inspiration, and plenty of energy! Here’s a little behind-the-scenes look at how our booth is coming together just before the European Society of Cardiology Congress begins.

We’re almost ready — see you there!

EAS is now on-site at European Society of Cardiology Congress and ready to meet you at booth F810 in hall 2B! Come by, s...
27/08/2026

EAS is now on-site at European Society of Cardiology Congress and ready to meet you at booth F810 in hall 2B! Come by, say hello, and learn more about who we are, our activities & everything happening at our society.

And don’t miss the chance to hear more about our EAS Congress in Gothenburg next year! We look forward to seeing you soon!

The European Atherosclerosis Society was proud to contribute to the success of VAS 2026 in Ninh Binh, Vietnam.Represente...
25/08/2026

The European Atherosclerosis Society was proud to contribute to the success of VAS 2026 in Ninh Binh, Vietnam.

Represented by Prof. Børge Nordestgaard, EAS played a key role in the VAS–EAS–IAS–APSAVD Joint Session, strengthening international scientific exchange and collaboration in atherosclerosis and cardiovascular disease.

A great example of EAS’s commitment to advancing knowledge and building global partnerships.

Adress

Första Långgatan 4A
Gothenburg
41303

Webbplats

Aviseringar

Var den första att veta och låt oss skicka ett mail när European Atherosclerosis Society (EAS) & Congress postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Affären

Skicka ett meddelande till European Atherosclerosis Society (EAS) & Congress:

Genvägar

Dela